Radiopharmaceuticals: sixteen years of deal data on where the field goes next
Buyers have concluded that radiopharmaceuticals are a platform business, and they are paying platform prices.
Analysis
Behind the Headlines: How the Leaders Really Performed
Read together rather than one at a time, the quarter divides along four lines, and none of them is visible in a headline growth rate.
7 Market Access Trends Reshaping Pharma by 2027
The rules of pharmaceutical market access are being rewritten. From IRA-mandated price ceilings to AI-driven outcomes contracting.
The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning
A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.